Document is current
Any future updates will be listed below
-
Authors
Mustapa, Mohd Nubli https://orcid.org/0009-0007-2781-1523
Hughes, Rod
Jensen, Tina J
Dosanjh, Davinder P
Konstantinidis, Kyriakos V
Jonsson, Julia
Nemes, Szilárd
Jevnikar, Zala
Jones, Michael
Adams, Amanda
Belvisi, Maria G
Akuthota, Praveen
Kocks, Janwillem W H
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct06020014 at ClinicalTrials.govnct01914757 at ClinicalTrials.govDocuments that mention this clinical trial
Phase 2a randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of londamocitinib (AZD4604) two times per day for 12 weeks in adult patients with moderate-to-severe asthma uncontrolled on medium-high-dose ICS-LABA
https://doi.org/10.1136/bmjresp-2025-003589
nct01928771 at ClinicalTrials.govDocuments that mention this clinical trial
Phase 2a randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of londamocitinib (AZD4604) two times per day for 12 weeks in adult patients with moderate-to-severe asthma uncontrolled on medium-high-dose ICS-LABA
https://doi.org/10.1136/bmjresp-2025-003589
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
https://doi.org/10.1016/s0140-6736(16)31322-8
Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab
https://doi.org/10.1007/s12325-022-02098-1
P68 Asthma symptom improvements with benralizumab are associated with improvements in activity functions and quality of life for patients with severe, uncontrolled asthma: results of pooled phase iii benralizumab studies
https://doi.org/10.1136/thoraxjnl-2017-210983.210
S117 Clinical remission in patients with severe eosinophilic asthma: an analysis of SIROCCO and CALIMA trial data
https://doi.org/10.1136/thorax-2023-btsabstracts.123
nct06020014 at ClinicalTrials.govDocuments that mention this clinical trial
Phase 2a randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of londamocitinib (AZD4604) two times per day for 12 weeks in adult patients with moderate-to-severe asthma uncontrolled on medium-high-dose ICS-LABA
https://doi.org/10.1136/bmjresp-2025-003589
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
https://doi.org/10.1016/s0140-6736(16)31324-1
Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab
https://doi.org/10.1007/s12325-022-02098-1
P68 Asthma symptom improvements with benralizumab are associated with improvements in activity functions and quality of life for patients with severe, uncontrolled asthma: results of pooled phase iii benralizumab studies
https://doi.org/10.1136/thoraxjnl-2017-210983.210
S117 Clinical remission in patients with severe eosinophilic asthma: an analysis of SIROCCO and CALIMA trial data
https://doi.org/10.1136/thorax-2023-btsabstracts.123
nct01914757 at ClinicalTrials.govDocuments that mention this clinical trial
Phase 2a randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of londamocitinib (AZD4604) two times per day for 12 weeks in adult patients with moderate-to-severe asthma uncontrolled on medium-high-dose ICS-LABA
https://doi.org/10.1136/bmjresp-2025-003589
nct01928771 at ClinicalTrials.govDocuments that mention this clinical trial
Phase 2a randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of londamocitinib (AZD4604) two times per day for 12 weeks in adult patients with moderate-to-severe asthma uncontrolled on medium-high-dose ICS-LABA
https://doi.org/10.1136/bmjresp-2025-003589
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
https://doi.org/10.1016/s0140-6736(16)31322-8
Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab
https://doi.org/10.1007/s12325-022-02098-1
P68 Asthma symptom improvements with benralizumab are associated with improvements in activity functions and quality of life for patients with severe, uncontrolled asthma: results of pooled phase iii benralizumab studies
https://doi.org/10.1136/thoraxjnl-2017-210983.210
S117 Clinical remission in patients with severe eosinophilic asthma: an analysis of SIROCCO and CALIMA trial data
https://doi.org/10.1136/thorax-2023-btsabstracts.123
Documents that mention this clinical trial
Phase 2a randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of londamocitinib (AZD4604) two times per day for 12 weeks in adult patients with moderate-to-severe asthma uncontrolled on medium-high-dose ICS-LABA
https://doi.org/10.1136/bmjresp-2025-003589
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
https://doi.org/10.1016/s0140-6736(16)31324-1
Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab
https://doi.org/10.1007/s12325-022-02098-1
P68 Asthma symptom improvements with benralizumab are associated with improvements in activity functions and quality of life for patients with severe, uncontrolled asthma: results of pooled phase iii benralizumab studies
https://doi.org/10.1136/thoraxjnl-2017-210983.210
S117 Clinical remission in patients with severe eosinophilic asthma: an analysis of SIROCCO and CALIMA trial data
https://doi.org/10.1136/thorax-2023-btsabstracts.123
-
Funding
Funding for this research was provided by:
AstraZeneca
- License Information
